Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug ...
I’m a Harvard-educated doctor — this bad nightly habit can increase your risk of heart disease
Experts recommend brushing at least twice a day and flossing once a day to eliminate plaque-forming bacteria that could ...
Medscape16h
Antidepressants Linked to Sudden Cardiac Death Risk, Early Results Suggest
Use of antidepressants for 6 or more years is linked to an increased risk for sudden cardiac death, but it’s unclear if the ...